Form 10-Q - Quarterly report [Sections 13 or 15(d)]

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

MARK ONE

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the Quarterly Period ended March 31, 2024; or

 

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the transition period from ________ to ________

 

WORLD HEALTH ENERGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		59-2762023
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

 

1825 NW Corporate Blvd. Suite 110, Boca Raton, FL		33431
(Address of principal executive offices)		Zip Code

 

[phone]

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☐		Smaller reporting company	☒
			Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of May 20, 2024, there were issued and outstanding 520,796,074,663 shares of the registrant’s common stock, par value $0.00001 per share, were outstanding.

 

 

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

Form 10-Q

March 31, 2024

 

	Page
PART I — FINANCIAL INFORMATION
Item 1 – Financial Statements – Unaudited	3
Condensed Consolidated Balance Sheets – March 31, 2024 and December 31, 2023	4
Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023	5
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three months ended March 31, 2024 and 2023	6
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023	7
Notes to Condensed Consolidated Financial Statements	8
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3 – Quantitative and Qualitative Disclosures About Market Risk	21
Item 4 – Controls and Procedures	21
Item 1 – Legal Proceedings	22
Item 1A – Risk Factors	23
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3 – Defaults upon Senior Securities	23
Item 4 – Mine Safety Disclosures	23
Item 5 – Other Information	23
Item 6 – Exhibits	23
Exhibit Index	23
SIGNATURES	24

 

i

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF MARCH 31, 2024

 

(UNAUDITED)

 

2

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF MARCH 31, 2024

IN U.S. DOLLARS

(UNAUDITED)

 

TABLE OF CONTENTS

 

	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Interim Condensed Consolidated Balance Sheets	4
Interim Condensed Consolidated Statements of Operations and Comprehensive Loss	5
Interim Condensed Consolidated Statements of Stockholders’ Equity	6
Interim Condensed Consolidated Statements of Cash Flows	7
Notes to Interim condensed consolidated financial statements	8 - 13

 

3

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(U.S. dollars except share and per share data)

 

		March 31,				December 31,
		2024				2023
Assets
Current Assets
Cash and cash equivalents			112,887				46,435
Accounts receivable, net of allowance for credit losses of $5,378 and $7,545 as of March 31, 2024 and December 31, 2023. respectively			51,080				51,011
Inventory			11,767				4,699
Other current assets			191,322				148,749
Total Current assets			367,056				250,894
Non-current assets
Right-of-use asset			103,225				116,548
Long term prepaid expenses			25,122				25,496
Property and equipment, net			52,456				55,473
Funds in respect of employee rights upon termination			58,725				56,558
Intangible assets			9,693,958				9,693,958
Total non-current assets			9,933,486				9,948,033
Total assets			10,300,542				10,198,927
Liabilities and Stockholders’ Deficit
Current Liabilities
Short term credit from related party			80,339				-
Accounts payable			65,367				106,964
Short term operating lease liability			39,367				56,245
Other current liabilities			590,591				554,928
Total Current Liabilities			775,664				718,137
Non-current Liabilities
Liability for employee rights upon retirement			224,519				217,617
Long term loan from parent company			2,012,339				2,012,339
Long term operating lease liability			53,283				49,411
Deferred tax liability			872,456				872,456
Total non-current liabilities			3,162,597				3,151,823
Total liabilities			3,938,261				3,869,960
Stockholders’ Deficit (Note 3)
Series A preferred stock $0.0007 par value, 10,000,000 shares authorized, 5,000,000 shares issued and outstanding as of March 31, 2024, and December 31, 2023			3,500				3,500
Preferred stock, value			3,500				3,500
Common stock $0.00001 par value, 750,000,000,000 shares authorized as of March 31, 2024 and December 31, 2023. 520,796,074,663 shares issued and outstanding as of March 31, 2024 and December 31, 2023.			67,162,651				67,162,651
Additional paid-in capital			(33,013,008	)			(33,985,758	)
Treasury stock at cost – 20,000,000,000 shares of common stock			(8,000,000	)			(8,000,000	)
Proceeds on account of shares			920,173				450,000
Accumulated other comprehensive loss			(18,900	)			(17,779	)
Accumulated deficit			(24,398,373	)			(23,015,196	)
Total Company’s stockholders’ equity			2,656,043				2,597,418
Non-controlling interests			3,706,238				3,731,549
Total stockholders’ equity			6,362,281				6,328,967
Total liabilities and stockholders’ equity			10,300,542				10,198,927

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

4

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars except share and per share data)

 

		2024				2023
		Three months ended
		March 31
		2024				2023
Revenues			32,876				32,340
Cost of sales			(11,682	)			-
Gross profit			21,194				32,340
Research and development expenses			(446,384	)			(502,935	)
Selling and marketing expenses			(27,199	)			(26,669	)
General and administrative expenses			(955,131	)			(1,984,458	)
Operating loss			(1,407,520	)			(2,481,722	)
Financing income, net			109				4,887
Loss before equity in net loss of equity investments			(1,407,411	)			(2,476,835	)
Less: Equity in net loss of equity investments			-				(477	)
Net loss			(1,407,411	)			(2,477,312	)
Net loss attributable to non-controlling interests			24,234				13,012
Net loss attributable to the Company’s stockholders			(1,383,177	)			(2,464,300	)
Basic and diluted net loss per share			(0.00	)			(0.00	)
Weighted average number of shares outstanding used in computing basic and diluted net loss per share			522,762,226,201				516,812,963,552
Comprehensive loss:
Net loss			(1,407,411	)			(2,477,312	)
Other comprehensive loss - Foreign currency translation adjustments			(1,121	)			(2,273	)
Comprehensive loss			(1,408,532	)			(2,479,585	)
Net - loss attributable to equity investments			24,234				13,012
Other comprehensive loss attributable to non-controlling interests			(1,077	)			(1,216	)
Comprehensive loss attributable to the Company’s stockholders			(1,385,375	)			(2,467,789	)

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

5

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(U.S. dollars, except share and per share data)

 

		Number of Shares				Amount				Number of Shares				Amount				paid-in capital				account of shares				Treasury shares				Comprehensive Income				Accumulated deficit				stockholders’ equity (deficit)				Non-Controlling Interest				equity (deficit)
		Series A Preferred Stock								Common Stock								Additional				Proceeds on								Accumulated Other								Total Company’s								Total stockholders’
		Number of Shares				Amount				Number of Shares				Amount				paid-in capital				account of shares				Treasury shares				Comprehensive Income				Accumulated deficit				stockholders’ equity (deficit)				Non-Controlling Interest				equity (deficit)
BALANCE AS OF DECEMBER 31, 2023			5,000,000				3,500				520,796,074,663				67,162,651				(33,985,758	)			450,000				(8,000,000	)			(17,779	)			(23,015,196	)			2,597,418				3,731,549				6,328,967
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2024:
Share-based payment to employees and services providers			-				-				-				-				972,750								-				-				-				972,750				-				972,750
Proceeds on account of shares			-				-				-				-				-				470,173				-				-				-				470,173				-				470,173
Other comprehensive loss			-				-				-				-				-				-				-				(1,121	)			-				(1,121	)			(1,077	)			(2,198	)
Net loss			-				-				-				-																				(1,383,177	)			(1,383,177	)			(24,234	)			(1,407,411	)
BALANCE AS OF MARCH 31, 2024			5,000,000				3,500				520,796,074,663				67,162,651				(33,013,008	)			920,173				(8,000,000	)			(18,900	)			(24,398,373	)			2,656,043				3,706,238				6,362,281

 

		Series A Preferred Stock								Common Stock								Additional				Proceeds on								Accumulated Other								Total Company’s								Total stockholders’
		Number of Shares				Amount				Number of Shares				Amount				paid-in capital				account of shares				Treasury shares				Comprehensive Income				Accumulated deficit				stockholders’ equity (deficit)				Non-Controlling Interest				equity (deficit)
BALANCE AS OF DECEMBER 31, 2022			5,000,000				3,500				516,302,741,330				67,117,718				(40,614,231	)			-				(8,000,000	)			(2,611	)			(16,035,848	)			2,468,528				3,815,844				6,284,372
BALANCE			5,000,000				3,500				516,302,741,330				67,117,718				(40,614,231	)			-				(8,000,000	)			(2,611	)			(16,035,848	)			2,468,528				3,815,844				6,284,372
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2023:
Issuance of shares			-				-				1,640,000,000				16,400				512,600				-				-				-				-				529,000				-				529,000
Share-based payment to employees and services providers			-				-				-				-				2,219,109				-				-				-				-				2,219,109				-				2,219,109
Other comprehensive loss			-				-				-				-				-				-				-				(2,273	)							(2,273	)			(1,216	)			(3,489	)
Net loss			-				-				-				-																				(2,464,300	)			(2,464,300	)			(13,012	)			(2,477,312	)
BALANCE AS OF MARCH 31, 2023			5,000,000				3,500				517,942,741,330				67,134,118				(37,882,522	)			-				(8,000,000	)			(4,884	)			(18,500,148	)			2,750,064				3,801,616				6,551,680
BALANCE			5,000,000				3,500				517,942,741,330				67,134,118				(37,882,522	)			-				(8,000,000	)			(4,884	)			(18,500,148	)			2,750,064				3,801,616				6,551,680

 

6

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars)

 

		2024				2023
		Three months ended
		March 31,
		2024				2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period			(1,407,411	)			(2,477,312	)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:
Depreciation			5,082				4,268
Increase in liability for employee rights upon retirement			6,902				12,045
Equity in losses of non-consolidated entity			-				477
Share-based compensation expense			972,750				2,244,405
Change in operating lease liability			319				(3,008	)
Increase in accounts receivable			(70	)			(2,677	)
Increase in other current assets			(37,310	)			(4,565	)
Decrease in accounts payable			(41,596	)			(15,920	)
Decrease in other accounts liabilities			31,460				(40,181	)
Net cash used in operating activities			(469,874	)			(282,468	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Loans repaid by (granted to) related parties			(11,956	)			1,530
Increase in funds in respect of employee rights upon retirement			(2,167	)			-
Purchase of property and equipment			(2,065	)			(6,109	)
Net cash used in investing activities			(16,188	)			(4,579	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock issued for cash			-				60,000
Loan received from related party			80,339				-
Proceeds on account of shares			470,173				325,000
Net cash provided by financing activities			550,512				385,000
Effect of exchange rate changes on cash and cash equivalents			2,002				1,290
INCREASE IN CASH AND CASH EQUIVALENTS			66,452				99,243
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD			46,435				56,346
CASH AND CASH EQUIVALENTS AT END OF PERIOD			112,887				155,589
Supplemental disclosure of cash flow information:
Non cash transactions:
Issuance of share in exchange for debt			-				144,000

 

The accompanying notes are an integral part of the condensed consolidated financial statement

 

7

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL

 

A.

Operations

 

World Health Energy Holdings, Inc. (the “Company” or “WHEN”) was formed on May 21, 1986 under the laws of the State of Delaware. The Company has invested in a variety of internally developed software programs that it strove to commercialize.

 

UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (“RNA”).

 

RNA is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity-related products.

 

In anticipation of the transaction contemplated under the SG Merger Agreement, SG 77 Inc., a Delaware corporation and a wholly-owned subsidiary of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

 

B.

SG Transaction

 

On April 27, 2020, the Company completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (“SG Merger Agreement”) among the Company, R2GA, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Sub”), UCG, SG, and RNA. Under the terms of the SG Merger Agreement, R2GA merged with SG, with SG as the surviving corporation and a wholly-owned subsidiary of the Company (“SG Merger”). The SG Merger was effective as of April 27, 2020, whereby SG became a direct and wholly owned subsidiary of the Company and RNA became an indirect wholly owned subsidiary of the Company.

 

As consideration for the SG Merger, the Company issued 3,870,000 Series B convertible preferred stock, par value $0.0007 per share, to UCG. Each share of the Series B convertible preferred stock will automatically convert into 100,000 shares of common stock, par value $0.0007, for an aggregate amount of 387,000,000,000 shares of common stock, upon the filing with the Secretary of State of Delaware of an amendment to the Company’s certificate of incorporation increasing the number of authorized shares of common stock that the Company is authorized to issue from time to time.

 

On October 7, 2021, and following the approval by the stockholders, the Company increase its authorized shares to 750,000,000,000 (from 110,000,000,000 shares) and changed the par value of the common stock to $0.00001 (from $0.0007).

 

Following the effectiveness of the Amendment referred to above, on December 3, 2021, the Company issued 387,000,000,000 shares of common stock to UCG upon the automatic conversion of all 3,870,000 outstanding Series B convertible preferred stock issued in April 2020 in connection with the acquisition of RNA from UCG.

 

The SG Merger was accounted for as a reverse asset acquisition. Under this method of accounting, SG was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the SG Merger: (i) SG’s stockholders owned a substantial majority of the voting rights in the combined company, (ii) SG designated a majority of the members of the initial board of directors of the combined company, and (iii) SG’s senior management holds all key positions in the senior management of the combined company. As a result of the reverse asset acquisition transaction, the shareholders of SG received the largest ownership interest in the Company, and SG was determined to be the “accounting acquirer” in the reverse asset acquisition transaction.

 

As a result, the historical financial statements of the Company were replaced with the historical financial statements of SG. The number of shares prior to the reverse capitalization have been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction.

 

8

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL (continued)

 

C.

CrossMobile Transaction

 

On March 22, 2022, the Company, CrossMobile Sp. z o.o, a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which Mr. Giora Rosenzweig, held 40.67% and Mr. George Baumeohl held 3.33% of the issued preferred share capital of CrossMobile) entered into an Investment Agreement (“CrossMobile Agreement”) pursuant to which the Company is to purchase 26% of the outstanding common shares of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of the Company’s common stock (the “Initial Investment”).

 

On July 13, 2022, the Company issued 10,000,000,000 common shares with fair value of $4 million to Crossmobile to consummate the transaction.

 

CrossMobile is a licensed mobile virtual network operator in Poland, providing the necessary licenses and key infrastructure in the EU. With its involvement in CrossMobile, the Company expects to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

 

In addition, under the CrossMobile Agreement, the Company had the option, through January 22, 2024, to purchase additional shares of CrossMobile (“Additional Share Purchase Option”) such that following the additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding common shares on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile.

 

On October 25, 2022, the Company exercised the Additional Share Purchase Option and acquired the additional 25% shares of CrossMobile such that following the acquisition, the Company increased its holding from 26% to 51% of CrossMobile’s outstanding common stock on a fully diluted basis. In consideration for the exercise of the Additional Share Purchase Option, the Company issued 10,000,000 restricted common stock on November 28, 2022 to Crossmobile.

 

The Company, collectively with SG, RNA and CrossMobile are hereunder referred to as the “Group”.

 

D.

Board and Shareholder Authority for Reverse Stock Split

 

On May 17, 2023, Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (“Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 20,000-to-1 and 60,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant to the Reverse Stock Split, each one thousand or fifteen thousand shares of common stock, or any other figure within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware.

 

9

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL (continued)

 

E.

Liquidity

 

The Group is subject to certain inherent risks and uncertainties associated with the development of its business. To date, substantially all the Company’s efforts and investments have been devoted to the growth of its business, organically and inorganically. These investments have historically been funded by raising outside capital, and as a result of these efforts, the Company has generally incurred significant losses and used net cash outflows from operations since inception and it may continue to incur such losses and use net cash outflows for the foreseeable future until such time it reaches scale of profitability without needing to rely on funding from outside capital to sustain its operations.

 

During the three months ended March 31, 2024, the Company incurred a net loss of $1,407 thousands and used net cash flows in its operations of $470 thousands. As of March 31, 2024, the Company had unrestricted cash and cash equivalents of $113 thousands available to fund its operations, and an accumulated deficit of $24,398 thousands.

 

In response to the risks and uncertainties described above, the Group and George Baumeohl, a Company director, have entered into an investment agreement signed on November 1, 2022, where the director has committed to invest up to $3,000,000 through August 2025, as needed by the Company through the purchase of shares of the Company’s common stock. As of March 31, 2024 an amount of $1,694,767 out of the $3,000,000 was invested in the Company.

 

the Company continues to carefully evaluate its liquidity position and while it is difficult to predict its future liquidity requirements with certainty, the Company currently expects it will be able to generate sufficient liquidity to fund its operations over the next twelve months beyond the issuance date.

 

F.

Risk factors

 

The Group faces a number of risks, including uncertainties regarding finalization of the development process, demand and market acceptance of the Group’s products, the effects of technological changes, competition and the development of products by competitors. Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group’s future results. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and increased marketing efforts. As mentioned above, the Group has not yet generated significant revenues from its operations to fund its activities, and therefore the continuance of its activities as a going concern depends on the receipt of additional funding from its current stockholders and investors or from third parties.

 

G.

On October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Following the attack by Hamas on Israel’s southern border, Hezbollah in Lebanon also launched missile, rocket, drone and shooting attacks against Israeli military sites, troops and Israeli towns in northern Israel. In response to these attacks, the Israeli army has carried out a number of targeted strikes on sites belonging to Hezbollah in Lebanon and Syria. Recently, Iran has directly joined the hostilities against Israel by firing hundreds of drones, ballistic missiles and guided missiles to Israel causing further uncertainty in the region. While currently limited damage was registered in Israel from the Iranian attack, the situation is developing and could lead to additional wars and hostilities in the Middle East. It is possible that the hostilities with Hezbollah will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank, as well as other hostile countries, will join the hostilities. Such hostilities may include terror and missile attacks.

 

Certain of our consultants in Israel may be called up for reserve duty, in addition to employees of our service providers located in Israel, have been called, for service and such persons may be absent for an extended period of time. In the event that hostilities disrupt our ongoing operations, our ability to deliver or provide services in a timely manner to meet our contractual obligations towards customers and vendors could be materially and adversely affected.

 

10

 

 

WORLD HEALTH ENERGY HOLDINGS, INC.

 

NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL (continue)

 

The intensity and duration of Israel’s current war against Hamas is difficult to predict, as are such war’s economic implications on the Company’s business and operations and on Israel’s economy in general. These events may be intertwined with wider macroeconomic indications of a deterioration of Israel’s economic standing, which may have a material adverse effect on the Company and its ability to effectively conduct its operations.

 

Since this is an event that is not under the control of the Company, and matters such as the fighting continuing or stopping may affect the Company’s assessments, as at the reporting date the Company is unable to assess the extent of the effect of the war on its business activities and on the business activities of its subsidiaries, and on their medium and long term results. The Company is continuing to regularly follow developments on the matter and is examining the effects on its operations and the value of its assets.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Unaudited Interim Financial Statements

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the three-months ended March 31, 2024. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2024. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.

 

Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ, for the year ended December 31, 2023.

 

Principles of Consolidation

 

The consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.

 

Use of Estimates

 

The preparation of condensed interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates.

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023 and interim periods within annual periods beginning after December 15, 2024, and early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024, early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements.

 

 

11

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 3 – COMMON STOCK

 

a.

In January and February 2024, the Company received subscription proceeds of $470,173 under the November 1, 2022, investment agreement with Mr. Baumeohll in respect of which he is entitled to 1,174,417,500 shares of the Company’s common stock, at a per share price of $0.0004.

 

NOTE 4 - STOCK OPTIONS

 

1. The following table presents the Company’s stock option activity during the three months ended March 31, 2024:

 

		Number of Options				Weighted Average Exercise Price
Outstanding at December 31,2023			36,602,000,000				0.001
Granted			-				-
Exercised			-				-
Forfeited or expired			-				-
Outstanding at March 31,2024			36,602,000,000				0.001
Number of options exercisable at March 31, 2024			14,000,000,000				0.001

 

The aggregate intrinsic value of the awards outstanding as of March 31, 2024 is 3,660,200. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.0002 as of March 31, 2024, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

 

The stock options outstanding as of March 31, 2024, have been separated into exercise prices, as follows:

 

Exercise price			Stock options outstanding				Weighted average remaining contractual life – years				Stock options vested
			As of March 31, 2024
0.001				36,602,000,000				2.50				14,000,000,000
				36,602,000,000				2.50				14,000,000,000

 

The stock options outstanding as of March 31, 2023, have been separated into exercise prices, as follows:

 

Exercise price			Stock options outstanding				Weighted average remaining contractual life – years				Stock options vested
			As of March 31, 2023
0.001				46,602,000,000				3.50				9,600,000,000
				46,602,000,000				3.50				9,600,000,000

 

Compensation expense recorded by the Company in respect of its stock-based compensation awards for the three months ended March 31, 2024 and 2023 was $972,750 and $2,219,109, respectively and are included in the Statements of Operations.

 

As of March 31, 2024, the total share-based compensation costs not yet recognized related to unvested stock options was $3,315,588 million, which is expected to be recognized over the weighted-average remaining requisite service period of 1.39 years.

 

12

 

 

WORLD HEALTH ENERGY HOLDINGS, INC .

 

NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 5 – RELATED PARTIES

 

A.

Transactions and balances with related parties

 

		2024				2023
		Three months ended March 31
		2024				2023
		(Unaudited)				(Unaudited)
General and administrative expenses:
Salaries and fees to officers			396,199				806,943
(*) of which share based compensation			352,171				756,077
Research and development expenses:
Salaries and fees to officers			49,191				77,811
(*) of which share based compensation			27,029				51,979

 

B.

Balances with related parties and officers:

 

		2024				2023
		As of March 31,				As of December 31,
		2024				2023
		(Unaudited)
Other current assets			71,149				62,647
Other accounts liabilities			116,001				113,615
Liability for employee rights upon retirement			127,359				129,768
Long term loan from related party (*)			2,012,339				2,012,339

 

(*)

Received from UCG by December 31, 2021. The loan bears no interest.

 

 

13

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2024. Certain statements made in this discussion are “forward-looking statements” within the meaning of the private securities litigation reform act of 1995,. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

 

Overview

 

World Health Energy Holdings (“WHEN” or the “Company” or “us” ) is primarily engaged in the global telecom and cybersecurity technology field. On April 27, 2020, WHEN completed a reverse triangular merger pursuant to the Merger Agreement among the Company, R2GA, UCG, SG, and RNA. Under the terms of the Merger Agreement, R2GA merged with and into SG, with SG remaining as the surviving corporation and a wholly-owned subsidiary of the Company. The Merger became effective as of April 27, 2020. Each of Gaya Rozensweig and George Baumeohl, directors of the Company, are also the sole shareholders and directors of UCG.

 

RNA is primarily a research and development company that has been performing software design services in the field of cybersecurity. SG is primarily engaged in the marketing and distribution of cybersecurity related products. In anticipation of the transaction contemplated under the Merger Agreement, SG was formed and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.

 

Following the closing, each of SG 77 and RNA became wholly-owned subsidiaries of the Company.

 

14

 

 

Acquisition of CrossMobile

 

On March 22, 2022 the Company, CrossMobile Sp z o.o., a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which our CEO, Giora Rosenzweig, holds 40.67% and George Baumeohl, a director, holds 3.33%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company purchased in July 2022 an initial 26% equity stake of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company . In addition, for 18 months following the date of the Agreement, the Company has the option to purchase additional shares of CrossMobile, (the “Additional Share Purchase Option”), such that following such additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis. On October 25, 2022, the Company exercised the Additional Share Purchase Option to acquire such additional shares of CrossMobile and the Company now holds approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis and proportionally voting rights. In consideration for the exercise of the Additional Share Purchase Option, the Company issued to CrossMobile an additional 10,000,000 shares of the Company’s common stock.

 

CrossMobile provides public mobile telephone services in Europe, (without its own radio infrastructure) We believe that the acquisition of CrossMobile provides an opportunity in our evolution and provides us with a strong foothold in the European mobile telecom market. CrossMobile is planning to roll-out a comprehensive suite of value-added services for B2B and B2C customers in the telecom industry.

 

With our involvement in CrossMobile, we expect to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.

 

The global telecom services market size was valued at USD $172.32 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030 ¹. The global cyber security market size is projected to grow from billion in 2023 to $424.97 billion in 2030, at a CAGR of 4.51%² during the forecast years. By combining the telecom focus with our existing cyber security product offering, our plan is to bring to market a new standard of service in value added telecom and security solutions for B2B and B2C customers alike.

 

Through the date of this report, CrossMobile signed up approximately 2,800 paying subscribers, including B2B and B2C subscribers. CrossMobile intends during the next 12 months to build a strong telecom brand empowered by ‘state of the art’ technology, competitive pricing and a product mix including proprietary AI and WHEN’s cybersecurity solutions.

 

Acquisition of Instaview

 

On Feb. 26, 2023 we completed the acquisition of an initial 26% of Instaview Ltd. (“Instaview”), an emerging technology company in the field of AI-based image processing systems, thermal cameras, home and enterprise security, livestock tracking and control appliances plus much more.

 

Instaview is engaged in the field of image processing systems and thermal cameras. Over the past 18 years, Instview has provided innovative security and managing solutions in hundreds of projects in Israel and overseas.

 

During the fourth quarter of 2023, the Company amortized its investment in InstaView and recorded an impairment charge of $151,015.

 

1 Grand View Research, from https://www.grandviewresearch.com/industry-analysis/global-telecom-services-market

2 https://www.fortunebusinessinsights.com/industry-reports/cyber-security-market-101165

 

Combined WHEN Product Offerings

 

Our product offerings are comprised of three complementary segments, namely

 

	1.	Cyber Care, which is the long standing and core business segment of WHEN
	2.	AI based image processing systems such as audio-video systems and security cameras solutions being an off-line extension of the on-line Cyber Care services entered through the acquisition of 26% shares in Instaview
	3.	Mobile telecom GSM which is a new business segment, linking the off and on line business segments entered through the recent acquisition of CrossMobile

 

All three are targeting commercial enterprises (B2B) and individual users (B2C).

 

15

 

 

Cyber Care

 

B2B Offerings—Our B2B Cybersecurity system software development and implementation program focuses on developing a threat management software that provides innovative solutions for the constantly evolving cyber challenges of businesses, non-governmental organizations (NGO’s) and governmental entities.

 

In 2021 we launched OTOGRAPH, our comprehensive cybersecurity and information security system, to enable business enterprises to monitor, analyze and prevent suspicious or harmful behavior on corporate networks and connected devices. The OTOGRAPH is designed to analyze and prevent internal or external abuse or abnormal activity on enterprise devices, such as PCs, mobile phones, servers or any other operating system (OS)-based Internet of things (IOT) devices. IoT devices are the nonstandard computing devices that connect wirelessly to a network and have the ability to transmit data.

 

The rapid transition to open and cloud-based remote workforce has exposed businesses and organizations across the world to higher risks of cyber-attacks and information security breaches. To enable businesses to better protect their data and workflow, we developed a Business Behavioral Analysis (BBA) system that enables business leaders to track all activity from any given location on a one-stop dashboard. Developed over the past two years, OTOGRAPH provides aggregated data and a wide variety of real-time analytics such as real time monitoring of online behavior, applications and system behavior, data breaches, internal and external connections analytics, productivity analysis and psycholinguistic analysis. Corporations and organizations can then use the dashboard to detect suspicious human or device activities that put their company at risk.

 

OTOGRAPH was developed based on based on a state of the art intelligence technology combined with AI technology that processes and analyzes massive amounts of behavioral and communication data and enables organizations to make real time accurate preventive assessments and decisions to protect company assets and ensure operational efficiency. OTOGRAPH deploys a unique Business Behavioral Analysis (BBA) machine learning software. Behavioral digital data is extracted from all endpoint devices that are connected to the company’s network infrastructure – whether physically, wirelessly or remotely. The data is processed and analyzed to learn and to reveal the unique digital behavioral pattern of the organization as a whole and of every endpoint or individual.

 

OTOGRAPH then sets baselines of normal patterns for each, and constantly searches for anomalies – deviations from those expected patterns. The anomalies are detected automatically and instantly, categorized by their type and generate push alerts which are sent to the business leader’s dashboard and enabling him to respond to the threat.

 

OTOGRAPH is continuously learning and calibrating the normal patterns and their thresholds to minimize the number of false alarms and constantly adapt to the changing needs of organizations in real time. Our B2C Cybersecurity division targets families concerned with external cyber threats and exposures in addition to monitoring a child’s behavioral patterns that may alert parents to potential tragedies caused by cyber bullying, pedophiles, other predators, and depression.

 

B2C

 

SG’s Parental System offers a comprehensive solution which is designed to enable parents wishing to observe their children’s online behavior to learn if they are accessing inappropriate websites and content and/or to protect them from a range of threats including cyberbullying, pedophiles and other predators and identity theft.

 

The Parental System line is positioned as the “ultimate parental cyber solution”. This system incorporates a range of features enabling parents to view and manage their children’s Android phones and devices. The key elements of our proprietary solutions include the following: analysis of all incoming and outgoing written data; analysis of all incoming and outgoing audio communication; real time location tracking; environmental surroundings analysis; and cyber activity analysis.

 

16

 

 

The Parental System has similar features to those of the B2B yet tailored to fit the needs of parents and guardians to protect their children. Such variations focus on online behavioral patterns whether vocally, via short message service (“SMS”) or social media platforms. If there is a change in behavior patterns, the product is designed to immediately send the parent or adult guardian an alert. For example, as stated in several international reports, one of the identifiable indicators before suicide is social withdrawal, something which today appears as a significant decrease in text message exchanges. The system categorizes this decrease as a red flag. Moreover, there are certain words and phrases which increase in use prior to suicide which the system will detect these it will put them in the red flag category.*

 

* https://www.mayoclinic.org/healthy-lifestyle/tween-and-teen-health/in-depth/teen-suicide/art-20044308

 

While analyzing voice calls based on; tone of speech, lengths of the conversation and the frequency of calls, Parental System Analytics is capable of identifying changes in behavioral patterns and flagging these changes. For example, studies showed that with deteriorating mental health, the frequency of calls decreases and the sentences along with the length of the conversations get shorter. Any such discrepancy in behavior patterns will send a real time alert to the parent or legal guardian, potentially avoiding a tragedy.

 

Strategy Cyber Care: We believe that the technology underlying our product offering is our primary competitive advantage. The strength of our solution is driven by several proprietary technologies and methodologies that we have developed, coupled with how we have combined them into our highly versatile platform incl. the mobile telecom platform discussed below. These advantages enable our end users to

 

	●	Prevent trade secret and data leakage;
	●	Protect against hackers;
	●	Minimize loss of productivity;
	●	Detect embezzlements and thefts;
	●	Defend employees from harassments;
	●	Prevent talent and client poaching;
	●	Avoid human errors;
	●	Develop a new level of decision-making ability based on accurate and real-time data; and
	●	Assist parents and legal guardians in monitoring their minor children’s’ cyber online activities.

 

The Company’s go-to-market strategy focuses principally on generating revenue from software, services and licensing. The Company intends to drive revenue growth and to achieve margins that are consistent with those of other enterprise software companies.

 

We currently intend to sell substantially all of our products and services to distributors and resellers, which will sell to end-user customers, which we refer to in this report as our customers.

 

The implementation of our strategies is subject to our raising significant cash resources, of which no assurance can be provided that we will be successful in raising the needed capital on commercially reasonable terms. As of the date of this prospectus, we have no commitments for any capital raise.

 

Mobile telecom GSM

 

Following the first step, our next planned strategy is to add the advanced B2B and B2B Cyber Care bundled with the audio-video systems and security cameras solution and offer them as an integrated part of our GSM solutions. This will give our B2B the possibility to use the AI and BBA as a tool to increase not only security but as well efficiency in sales organizations where soft skills, emotions and personal relations are crucial.

 

17

 

 

In respect to the B2C market our strategy is to give families a tool to protect their assets and entire households in particular kids or pets and evenelderly members being fragile newcomers in the world of e-commerce, on-line banking and on-line dating.

 

The third step expected to be initiated in fourth quarter of 2024 in is to copy and paste the same scenario of combining Cyber Care and Mobile Telecom to other selected markets in North Africa, the USA and Europe.

 

Comparison of the Three Months Ended March 31, 2024 to the Three Months Ended March 31, 2023

 

		Three months ended March 31, 2024
		2024				2023
Revenues		$	32,876				32,340
Cost of revenues			(11,682	)			-
Gross profit			21,194				32,340
Operating Expenses
Research and development expenses			(446,384	)			(502,935	)
Selling and marketing expenses			(27,199	)			(26,669	)
General and administrative expenses			(955,131	)			(1,984,458	)
Operating loss			(1,407,520	)			(2,481,722	)
Financing income, net			109				4,887
Loss before equity in net loss of equity investments			(1,407,411	)			(2,476,835	)
Less: Equity in net loss of equity investments			-				(477	)
Net loss			(1,407,411	)			(2,476,835	)
Net loss attributable to non-controlling interests			24,234				13,012
Net loss attributable to the Company’s stockholders			(1,383,177	)			(2,464,300	)

 

Revenues

 

Our total revenue consists of sales of our products and services.

 

Cost of revenues

 

Our cost of revenues includes cost of products sold.

 

Operating Expenses

 

Our current operating expenses consist of three components - research and development expenses, selling and marketing expenses and general and administrative expenses.

 

Research and Development Expenses, net

 

We expect to continue incurring substantial expenses for the next several years as we continue to develop our product lines. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred. The design and development activities will consume a large proportion of our current, as well as projected, resources.

 

Our research and development costs include costs are comprised of:

 

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

 

18

 

 

● fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

 

The following table discloses the breakdown of research and development expenses:

 

		Three Months Ended March 31,
		2024				2023
Salaries and related expenses		$	75,483				62,344
Share-based compensation expenses			268,990				400,524
Subcontractors and other development costs			37,647				8,832
Depreciation and amortization			5,082				4,268
Rent and office maintenance			42,031				22,624
Other expenses			17,151				4,343
Total		$	446,384				502,935

 

Selling and Marketing Expenses

 

Selling and marketing expenses consist primarily of salaries and related expenses, professional services and other expenses.

 

The following table discloses the breakdown of selling and marketing expenses:

 

		Three Months Ended March 31,
		2024				2023
Salaries and related expenses			27,199				26,669
Total		$	27,199				26,669

 

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts in 2024 following the acquisition of Cross Mobile and our marketing efforts to build new Telecom operators with standard packages of Voice, SMS and Data in Poland and International Roaming .

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries and related expenses, professional services, rent and office maintenance and other non-personnel related expenses.

 

The following table discloses the breakdown of general and administrative expenses:

 

		Three Months Ended March 31
		2024				2023
Salaries and related expenses		$	58,385				94,439
Share-based compensation expenses			703,759				1,846,363
Professional services			161,611				20,342
Rent and office maintenance			28,266				22,779
Other expenses			3,110				535
Total		$	955,131				1,984,458

 

19

 

 

Revenues

 

Revenues for the three months ended March 31, 2024 and 2023 were $32,876 and $32,340, respectively.

 

Research and Development Expenses. Research and development expenses consist of salaries and related expenses, share-based compensation expenses, consulting fees, service providers’ costs and overhead expenses. Research and development expenses decreased from $502,935 during the three months ended March 31, 2023 to $446,384 during the three months ended March 31, 2024. The decrease resulted primarily from decrease in non-cash share-based compensation expenses, partially offset by increase in consulting fees and service providers’ costs associated with our development activities, rent and maintenance costs and salaries and related expenses.

 

Selling and Marketing Expenses. Selling and marketing expenses consist primarily of salaries and related expenses. Selling and marketing expenses for the three months ended March 31, 2024 amounted to $27,199 as compared to $26,669 for the three months ended March 31, 2023.

 

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses, share-based compensation expenses and other non-personnel related expenses such as legal expenses. General and administrative expenses decreased from $1,984,458 for the three months ended March 31, 2023 to $955,131 in the three months ended March 31, 2024. The decrease is primarily attributed to the decrease in non-cash share-based compensation expenses and salaries and related expenses partially offset by increase in professional services.

 

Financing Income, Net. Financing income, net decreased from $4,887 of financing income for the three months ended March 31, 2023 to financing income, net of $109 for the three months ended March 31, 2024. The decrease is mainly a result of currency exchange differences between the Dollar and the New Israeli Shekel offset by increase in interest from related parties.

 

Net Loss. As a result of the foregoing, our net loss for the three months ended March 31, 2024 was $1,407,520 compared to $2,481,722 for the three months ended March 31, 2023.

 

Financial Condition, Liquidity and Capital Resources

 

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. At March 31, 2024 and 2023, we had current assets of $376,056 and $354,313, respectively, and total assets of $10,300,542 and $10,452,865 respectively. We had current liabilities of $775,664 and 741,333 as of March 31, 2024 and 2023, respectively and total liabilities of $3,938,261 as compared to $3,901,185 as of March 31, 2024 and 2023, respectively.

 

At March 31, 2024, we had a cash balance of $112,887 compared to the cash balance of $155,589 as of March 31, 2023. We have no cash equivalents.

 

At March 31, 2024, we had a negative working capital of $408,608 as compared with a working capital deficiency of $387,020 at March 31, 2024.

 

Financial Support

 

In November 2022, we entered into an investment agreement with George Baumeohl, our director, pursuant to which Mr. Baumeohl has agreed to support our operation by way of an equity investment of up to $3 million through August 2025, as needed. The agreement provides for sales of our common stock to Mr. Baumeohl at per share purchase prices ranging between $0.0003 and $0.0005. As of the date of this report, we received an aggregate of $1,844,767 from Mr. Baumeohl of which he is entitled to 3,403,584,167 shares of our common stock at a per share price ranging between $0.0003 and $0.0004.

 

Management believes that funds on hand, as well as the subscription proceeds that we are to receive on a periodic basis under the committed subscription agreements with our director, will enable us to fund our operations and capital expenditure requirements through the next twelve months. We are substantially dependent on the periodic investment by our director and any disruption of this arrangement will likely materially adversely affect our business.

 

20

 

 

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

 

Critical Accounting Policies

 

The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In preparing the consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated balance sheets and consolidated statements of operations. Actual results may differ significantly from those estimates.

 

While our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.

 

Off-Balance Sheet Arrangements We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures.

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer, to allow timely decisions regarding required disclosure. Management, with the participation of our Interim Chief Executive Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2024. Based on that evaluation, our management, including our Chief Executive Officer, concluded that our disclosure controls and procedures were not effective as of March 31, 2024.

 

21

 

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2023, our management concluded that our internal control over financial reporting was not effective at December 31, 2023. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The limitation of the Company’s internal control over financial reporting was due to the applied risk-based approach which is indicative of many small companies with limited number of staff in corporate functions. The identified weakness were:

 

●	Material Weakness – We did not maintain effective controls over certain aspects of the financial reporting process because we (i) lacked a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and (ii) we lacked controls over the disclosure of our business operations.
●	lack of segregation of duties Significant Deficiencies – Inadequate segregation of duties.

 

We expect to be materially dependent upon third parties to provide us with accounting consulting services for the foreseeable future which we believe will mitigate the impact of the material weaknesses discussed above. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP and establish an audit committee and implement internal controls and procedures, there are no assurances that the material weaknesses and significant deficiencies in our disclosure controls and procedures will not result in errors in our financial statements which could lead to a restatement of those financial statements.

 

Changes in Internal Controls over Financial Reporting.

 

Except for the material weakness noted above, there have been no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II—OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

On October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The suit relates to the Stock Purchase Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate. The suit seeks declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the FSC transaction that are still outstanding.

 

On or about, January 19, 2022, EL filed a lawsuit in the Delaware Court of Chancery seeking to remove the restrictive legend from all the shares of Common Stock held by EL (the “2022 Lawsuit”), which are approximately 23,000,000,000 shares. The Company is vigorously defending the 2022 Lawsuit, which is currently in the discovery. Trial is scheduled for May 5, 2025.

 

On June 24, 2022 the Company filed an amended complaint in Palm Beach County, Florida (CASE NO. 50-2020- CA-011735), alleging violation of Fla. Stat. 517.301, seeking declaratory relief with regard to the status of the shares held and transferred by EL, and seeking a temporary injunction with regard to the transfer of any subject shares.

 

The Florida Court dismissed the amended complaint based on the statute of limitations.

 

The Company intends to continue to vigorously pursue this action and avail itself of all options lawfully available to it.

 

22

 

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not aware of any such legal proceedings or claims against us.

 

ITEM 1A. RISK FACTORS

 

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect our business, financial condition, or future results.

 

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

 

On November 1, 2022, we entered into an investment agreement with George Baumeohl, Company’s director, pursuant to which Mr. Baumeohl has agreed to support Company’s operation by way of an equity investment of up to $3 million, as needed.

 

	a.	On January 1, 2024 the Company received subscription proceeds of $100,000 under the investment agreement with Mr. Baumeohl in respect of which he is entitled to 250,000,000 shares of Common Stock which have not been issued as of the date of this report
	b.	On February 12, 2024 the Company received subscription proceeds of $150,000 under the investment agreement with Mr. Baumeohl in respect of which he is entitled to 375,000,000 shares of Common Stock which have not been issued as of the date of this report.
	c.	On February 28, 2024 the Company received subscription proceeds of $200,000 under the investment agreement with Mr. Baumeohl in respect of which he is entitled to 500,000,000 shares of Common Stock which have not been issued as of the date of this report.

 

We relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) by virtue of Section 4(a)(2) thereof and/or Regulation S promulgated by the SEC under the Act with respect to the issuance of such securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None.

 

ITEM 5. OTHER INFORMATION:

 

During the fiscal quarter ended March 31, 2024, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.

 

ITEM 6. EXHIBITS

 

Exhibit Index:

 

31.1*		Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
32.1*		Certification of Interim Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

 

23

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

WORLD HEALTH ENERGY HOLDINGS, INC.
(Registrant)
By:	/s/ Giora Rozensweig
	Giora Rozensweig
	Interim Chief Executive Officer
	(Principal Executive Officer and Principal Financial and Accounting Officer)
Date:	May 20, 2024

 

24

 

EXHIBIT 31.1

 

RULE 13a-14(a) CERTIFICATION

 

I, Giora Rozensweig, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, of World Health Energy Holdings, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 20, 2024
/s/ Giora Rozensweig
Giora Rozensweig, Chief Executive Officer
(Principal Executive Officer and Principal Financial
and Accounting Officer)

 

 

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

 

In connection with the Quarterly Report on Form 10-Q of World Health Energy Holdings, Inc. (the “Company”) for the for the fiscal quarter ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Giora Rozensweig, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Giora Rozensweig
Giora Rozensweig
Chief Executive Officer (Principal Executive Officer and
Principal Financial and Accounting Officer)
May 20, 2024

 

 

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 20, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-30256
Entity Registrant Name	WORLD HEALTH ENERGY HOLDINGS, INC.
Entity Central Index Key	0000943535
Entity Tax Identification Number	59-2762023
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1825 NW Corporate Blvd.
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	(561)
Local Phone Number	870-0440
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		520,796,074,663

Condensed Interim Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 112,887	$ 46,435
Accounts receivable, net of allowance for credit losses of $5,378 and $7,545 as of March 31, 2024 and December 31, 2023. respectively	51,080	51,011
Inventory	11,767	4,699
Other current assets	191,322	148,749
Total Current assets	367,056	250,894
Non-current assets
Right-of-use asset	103,225	116,548
Long term prepaid expenses	25,122	25,496
Property and equipment, net	52,456	55,473
Funds in respect of employee rights upon termination	58,725	56,558
Intangible assets	9,693,958	9,693,958
Total non-current assets	9,933,486	9,948,033
Total assets	10,300,542	10,198,927
Current Liabilities
Short term credit from related party	80,339
Accounts payable	65,367	106,964
Short term operating lease liability	39,367	56,245
Other current liabilities	590,591	554,928
Total Current Liabilities	775,664	718,137
Non-current Liabilities
Liability for employee rights upon retirement	224,519	217,617
Long term loan from parent company	2,012,339	2,012,339
Long term operating lease liability	53,283	49,411
Deferred tax liability	872,456	872,456
Total non-current liabilities	3,162,597	3,151,823
Total liabilities	3,938,261	3,869,960
Stockholders’ Deficit (Note 3)
Common stock $0.00001 par value, 750,000,000,000 shares authorized as of March 31, 2024 and December 31, 2023. 520,796,074,663 shares issued and outstanding as of March 31, 2024 and December 31, 2023.	67,162,651	67,162,651
Additional paid-in capital	(33,013,008)	(33,985,758)
Treasury stock at cost – 20,000,000,000 shares of common stock	(8,000,000)	(8,000,000)
Proceeds on account of shares	920,173	450,000
Accumulated other comprehensive loss	(18,900)	(17,779)
Accumulated deficit	(24,398,373)	(23,015,196)
Total Company’s stockholders’ equity	2,656,043	2,597,418
Non-controlling interests	3,706,238	3,731,549
Total stockholders’ equity	6,362,281	6,328,967
Total liabilities and stockholders’ equity	10,300,542	10,198,927
Series A Preferred Stock [Member]
Stockholders’ Deficit (Note 3)
Preferred stock, value	$ 3,500	$ 3,500

Condensed Interim Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accounts receivable, net of allowance for credit losses	$ 5,378	$ 7,545
Common stock, par value	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	750,000,000,000	750,000,000,000
Common Stock , Shares Issued	520,796,074,663	520,796,074,663
Common Stock , Shares Outstanding	520,796,074,663	520,796,074,663
Treasury stock, shares	20,000,000,000	20,000,000,000
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0007	$ 0.0007
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	5,000,000	5,000,000
Preferred stock, shares outstanding	5,000,000	5,000,000

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 32,876	$ 32,340
Cost of sales	(11,682)
Gross profit	21,194	32,340
Research and development expenses	(446,384)	(502,935)
Selling and marketing expenses	(27,199)	(26,669)
General and administrative expenses	(955,131)	(1,984,458)
Operating loss	(1,407,520)	(2,481,722)
Financing income, net	109	4,887
Loss before equity in net loss of equity investments	(1,407,411)	(2,476,835)
Less: Equity in net loss of equity investments		(477)
Net loss	(1,407,411)	(2,477,312)
Net loss attributable to non-controlling interests	24,234	13,012
Net loss attributable to the Company’s stockholders	$ (1,383,177)	$ (2,464,300)
Diluted net loss per share	$ (0.00)	$ (0.00)
Net loss per share - Diluted	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding used in computing basic net loss per share	522,762,226,201	516,812,963,552
Weighted average number of shares outstanding used in computing diluted net loss per share	522,762,226,201	516,812,963,552
Comprehensive loss:
Other comprehensive loss - Foreign currency translation adjustments	$ (1,121)	$ (2,273)
Comprehensive loss	(1,408,532)	(2,479,585)
Net - loss attributable to equity investments	24,234	13,012
Other comprehensive loss attributable to non-controlling interests	(1,077)	(1,216)
Comprehensive loss attributable to the Company’s stockholders	$ (1,385,375)	$ (2,467,789)

Condensed Interim Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Series A Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Proceeds On Account Of Shares [Member]	Treasury Stock, Common [Member]	AOCI Including Portion Attributable to Noncontrolling Interest [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
BALANCE at Dec. 31, 2022	$ 3,500	$ 67,117,718	$ (40,614,231)		$ (8,000,000)	$ (2,611)	$ (16,035,848)	$ 2,468,528	$ 3,815,844	$ 6,284,372
Balance, shares at Dec. 31, 2022	5,000,000	516,302,741,330
Share-based payment to employees and services providers			2,219,109					2,219,109		2,219,109
Other comprehensive loss						(2,273)		(2,273)	(1,216)	(3,489)
Net loss							(2,464,300)	(2,464,300)	(13,012)	(2,477,312)
Issuance of shares		$ 16,400	512,600					529,000		529,000
Issuance of shares , shares		1,640,000,000
BALANCE at Mar. 31, 2023	$ 3,500	$ 67,134,118	(37,882,522)		(8,000,000)	(4,884)	(18,500,148)	2,750,064	3,801,616	6,551,680
Balance, shares at Mar. 31, 2023	5,000,000	517,942,741,330
BALANCE at Dec. 31, 2023	$ 3,500	$ 67,162,651	(33,985,758)	450,000	(8,000,000)	(17,779)	(23,015,196)	2,597,418	3,731,549	6,328,967
Balance, shares at Dec. 31, 2023	5,000,000	520,796,074,663
Proceeds on account of shares				470,173				470,173		470,173
Share-based payment to employees and services providers			972,750					972,750		972,750
Other comprehensive loss						(1,121)		(1,121)	(1,077)	(2,198)
Net loss							(1,383,177)	(1,383,177)	(24,234)	(1,407,411)
BALANCE at Mar. 31, 2024	$ 3,500	$ 67,162,651	$ (33,013,008)	$ 920,173	$ (8,000,000)	$ (18,900)	$ (24,398,373)	$ 2,656,043	$ 3,706,238	$ 6,362,281
Balance, shares at Mar. 31, 2024	5,000,000	520,796,074,663

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (1,407,411)	$ (2,477,312)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:
Depreciation	5,082	4,268
Increase in liability for employee rights upon retirement	6,902	12,045
Equity in losses of non-consolidated entity		477
Share-based compensation expense	972,750	2,244,405
Change in operating lease liability	319	(3,008)
Increase in accounts receivable	(70)	(2,677)
Increase in other current assets	(37,310)	(4,565)
Decrease in accounts payable	(41,596)	(15,920)
Decrease in other accounts liabilities	31,460	(40,181)
Net cash used in operating activities	(469,874)	(282,468)
CASH FLOWS FROM INVESTING ACTIVITIES:
Loans repaid by (granted to) related parties	(11,956)	1,530
Increase in funds in respect of employee rights upon retirement	(2,167)
Purchase of property and equipment	(2,065)	(6,109)
Net cash used in investing activities	(16,188)	(4,579)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock issued for cash		60,000
Loan received from related party	80,339
Proceeds on account of shares	470,173	325,000
Net cash provided by financing activities	550,512	385,000
Effect of exchange rate changes on cash and cash equivalents	2,002	1,290
INCREASE IN CASH AND CASH EQUIVALENTS	66,452	99,243
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	46,435	56,346
CASH AND CASH EQUIVALENTS AT END OF PERIOD	112,887	155,589
Non cash transactions:
Issuance of share in exchange for debt		$ 144,000

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (1,383,177)	$ (2,464,300)

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

GENERAL	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 – GENERAL   A. Operations   World Health Energy Holdings, Inc. (the “Company” or “WHEN”) was formed on May 21, 1986 under the laws of the State of Delaware. The Company has invested in a variety of internally developed software programs that it strove to commercialize.   UCG, INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns the issued and outstanding shares of RNA Ltd. (“RNA”).   RNA is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity-related products.   In anticipation of the transaction contemplated under the SG Merger Agreement, SG 77 Inc., a Delaware corporation and a wholly-owned subsidiary of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including the share ownership of RNA, were assigned to SG.   B. SG Transaction   On April 27, 2020, the Company completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (“SG Merger Agreement”) among the Company, R2GA, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Sub”), UCG, SG, and RNA. Under the terms of the SG Merger Agreement, R2GA merged with SG, with SG as the surviving corporation and a wholly-owned subsidiary of the Company (“SG Merger”). The SG Merger was effective as of April 27, 2020, whereby SG became a direct and wholly owned subsidiary of the Company and RNA became an indirect wholly owned subsidiary of the Company.   As consideration for the SG Merger, the Company issued 3,870,000 Series B convertible preferred stock, par value $0.0007 per share, to UCG. Each share of the Series B convertible preferred stock will automatically convert into 100,000 shares of common stock, par value $0.0007, for an aggregate amount of 387,000,000,000 shares of common stock, upon the filing with the Secretary of State of Delaware of an amendment to the Company’s certificate of incorporation increasing the number of authorized shares of common stock that the Company is authorized to issue from time to time.   On October 7, 2021, and following the approval by the stockholders, the Company increase its authorized shares to 750,000,000,000 (from 110,000,000,000 shares) and changed the par value of the common stock to $0.00001 (from $0.0007).   Following the effectiveness of the Amendment referred to above, on December 3, 2021, the Company issued 387,000,000,000 shares of common stock to UCG upon the automatic conversion of all 3,870,000 outstanding Series B convertible preferred stock issued in April 2020 in connection with the acquisition of RNA from UCG.   The SG Merger was accounted for as a reverse asset acquisition. Under this method of accounting, SG was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the SG Merger: (i) SG’s stockholders owned a substantial majority of the voting rights in the combined company, (ii) SG designated a majority of the members of the initial board of directors of the combined company, and (iii) SG’s senior management holds all key positions in the senior management of the combined company. As a result of the reverse asset acquisition transaction, the shareholders of SG received the largest ownership interest in the Company, and SG was determined to be the “accounting acquirer” in the reverse asset acquisition transaction.   As a result, the historical financial statements of the Company were replaced with the historical financial statements of SG. The number of shares prior to the reverse capitalization have been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the Recapitalization Transaction.     WORLD HEALTH ENERGY HOLDINGS, INC .   NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS   NOTE 1 – GENERAL (continued)   C. CrossMobile Transaction   On March 22, 2022, the Company, CrossMobile Sp. z o.o, a company formed under the laws of Poland (“CrossMobile”) and the shareholders of CrossMobile (of which Mr. Giora Rosenzweig, held 40.67% and Mr. George Baumeohl held 3.33% of the issued preferred share capital of CrossMobile) entered into an Investment Agreement (“CrossMobile Agreement”) pursuant to which the Company is to purchase 26% of the outstanding common shares of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of the Company’s common stock (the “Initial Investment”).   On July 13, 2022, the Company issued 10,000,000,000 common shares with fair value of $4 million to Crossmobile to consummate the transaction.   CrossMobile is a licensed mobile virtual network operator in Poland, providing the necessary licenses and key infrastructure in the EU. With its involvement in CrossMobile, the Company expects to provide advanced cybersecurity solutions and other next-generation value-added services to CrossMobile’s future product offerings.   In addition, under the CrossMobile Agreement, the Company had the option, through January 22, 2024, to purchase additional shares of CrossMobile (“Additional Share Purchase Option”) such that following the additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding common shares on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between the Company and CrossMobile.   On October 25, 2022, the Company exercised the Additional Share Purchase Option and acquired the additional 25% shares of CrossMobile such that following the acquisition, the Company increased its holding from 26% to 51% of CrossMobile’s outstanding common stock on a fully diluted basis. In consideration for the exercise of the Additional Share Purchase Option, the Company issued 10,000,000 restricted common stock on November 28, 2022 to Crossmobile.   The Company, collectively with SG, RNA and CrossMobile are hereunder referred to as the “Group”.   D. Board and Shareholder Authority for Reverse Stock Split   On May 17, 2023, Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (“Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 20,000-to-1 and 60,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant to the Reverse Stock Split, each one thousand or fifteen thousand shares of common stock, or any other figure within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware.     WORLD HEALTH ENERGY HOLDINGS, INC .   NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS   NOTE 1 – GENERAL (continued)   E. Liquidity   The Group is subject to certain inherent risks and uncertainties associated with the development of its business. To date, substantially all the Company’s efforts and investments have been devoted to the growth of its business, organically and inorganically. These investments have historically been funded by raising outside capital, and as a result of these efforts, the Company has generally incurred significant losses and used net cash outflows from operations since inception and it may continue to incur such losses and use net cash outflows for the foreseeable future until such time it reaches scale of profitability without needing to rely on funding from outside capital to sustain its operations.   During the three months ended March 31, 2024, the Company incurred a net loss of $1,407 thousands and used net cash flows in its operations of $470 thousands. As of March 31, 2024, the Company had unrestricted cash and cash equivalents of $113 thousands available to fund its operations, and an accumulated deficit of $24,398 thousands.   In response to the risks and uncertainties described above, the Group and George Baumeohl, a Company director, have entered into an investment agreement signed on November 1, 2022, where the director has committed to invest up to $3,000,000 through August 2025, as needed by the Company through the purchase of shares of the Company’s common stock. As of March 31, 2024 an amount of $1,694,767 out of the $3,000,000 was invested in the Company.   the Company continues to carefully evaluate its liquidity position and while it is difficult to predict its future liquidity requirements with certainty, the Company currently expects it will be able to generate sufficient liquidity to fund its operations over the next twelve months beyond the issuance date.   F. Risk factors   The Group faces a number of risks, including uncertainties regarding finalization of the development process, demand and market acceptance of the Group’s products, the effects of technological changes, competition and the development of products by competitors. Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group’s future results. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and increased marketing efforts. As mentioned above, the Group has not yet generated significant revenues from its operations to fund its activities, and therefore the continuance of its activities as a going concern depends on the receipt of additional funding from its current stockholders and investors or from third parties.   G. On October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Following the attack by Hamas on Israel’s southern border, Hezbollah in Lebanon also launched missile, rocket, drone and shooting attacks against Israeli military sites, troops and Israeli towns in northern Israel. In response to these attacks, the Israeli army has carried out a number of targeted strikes on sites belonging to Hezbollah in Lebanon and Syria. Recently, Iran has directly joined the hostilities against Israel by firing hundreds of drones, ballistic missiles and guided missiles to Israel causing further uncertainty in the region. While currently limited damage was registered in Israel from the Iranian attack, the situation is developing and could lead to additional wars and hostilities in the Middle East. It is possible that the hostilities with Hezbollah will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank, as well as other hostile countries, will join the hostilities. Such hostilities may include terror and missile attacks.   Certain of our consultants in Israel may be called up for reserve duty, in addition to employees of our service providers located in Israel, have been called, for service and such persons may be absent for an extended period of time. In the event that hostilities disrupt our ongoing operations, our ability to deliver or provide services in a timely manner to meet our contractual obligations towards customers and vendors could be materially and adversely affected.     WORLD HEALTH ENERGY HOLDINGS, INC.   NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS   NOTE 1 – GENERAL (continue)   The intensity and duration of Israel’s current war against Hamas is difficult to predict, as are such war’s economic implications on the Company’s business and operations and on Israel’s economy in general. These events may be intertwined with wider macroeconomic indications of a deterioration of Israel’s economic standing, which may have a material adverse effect on the Company and its ability to effectively conduct its operations.   Since this is an event that is not under the control of the Company, and matters such as the fighting continuing or stopping may affect the Company’s assessments, as at the reporting date the Company is unable to assess the extent of the effect of the war on its business activities and on the business activities of its subsidiaries, and on their medium and long term results. The Company is continuing to regularly follow developments on the matter and is examining the effects on its operations and the value of its assets.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION   Unaudited Interim Financial Statements   The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the three-months ended March 31, 2024. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2024. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.   Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ, for the year ended December 31, 2023.   Principles of Consolidation   The consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.   Use of Estimates   The preparation of condensed interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates.   Recently Issued Accounting Pronouncements Not Yet Adopted   In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023 and interim periods within annual periods beginning after December 15, 2024, and early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024, early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements.       WORLD HEALTH ENERGY HOLDINGS, INC .   NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

COMMON STOCK	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
COMMON STOCK	NOTE 3 – COMMON STOCK   a. In January and February 2024, the Company received subscription proceeds of $470,173 under the November 1, 2022, investment agreement with Mr. Baumeohll in respect of which he is entitled to 1,174,417,500 shares of the Company’s common stock, at a per share price of $0.0004.

STOCK OPTIONS	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 4 - STOCK OPTIONS   1. The following table presents the Company’s stock option activity during the three months ended March 31, 2024:       Number of Options     Weighted Average Exercise Price   Outstanding at December 31,2023     36,602,000,000       0.001   Granted     -       -   Exercised     -       -   Forfeited or expired     -       -   Outstanding at March 31,2024     36,602,000,000       0.001   Number of options exercisable at March 31, 2024     14,000,000,000       0.001     The aggregate intrinsic value of the awards outstanding as of March 31, 2024 is 3,660,200. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.0002 as of March 31, 2024, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.   The stock options outstanding as of March 31, 2024, have been separated into exercise prices, as follows:   Exercise price     Stock options outstanding     Weighted average remaining contractual life – years     Stock options vested         As of March 31, 2024   0.001       36,602,000,000       2.50       14,000,000,000           36,602,000,000       2.50       14,000,000,000     The stock options outstanding as of March 31, 2023, have been separated into exercise prices, as follows:   Exercise price     Stock options outstanding     Weighted average remaining contractual life – years     Stock options vested         As of March 31, 2023   0.001       46,602,000,000       3.50       9,600,000,000           46,602,000,000       3.50       9,600,000,000     Compensation expense recorded by the Company in respect of its stock-based compensation awards for the three months ended March 31, 2024 and 2023 was $972,750 and $2,219,109, respectively and are included in the Statements of Operations.   As of March 31, 2024, the total share-based compensation costs not yet recognized related to unvested stock options was $3,315,588 million, which is expected to be recognized over the weighted-average remaining requisite service period of 1.39 years.     WORLD HEALTH ENERGY HOLDINGS, INC .   NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

RELATED PARTIES	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 5 – RELATED PARTIES   A. Transactions and balances with related parties       2024     2023       Three months ended March 31       2024     2023       (Unaudited)     (Unaudited)                 General and administrative expenses:                 Salaries and fees to officers     396,199       806,943   (*) of which share based compensation     352,171       756,077                     Research and development expenses:                 Salaries and fees to officers     49,191       77,811   (*) of which share based compensation     27,029       51,979       B. Balances with related parties and officers:       2024     2023       As of March 31,     As of December 31,       2024     2023       (Unaudited)                           Other current assets     71,149       62,647   Other accounts liabilities     116,001       113,615   Liability for employee rights upon retirement     127,359       129,768   Long term loan from related party (*)     2,012,339       2,012,339       (*) Received from UCG by December 31, 2021. The loan bears no interest.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements   The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the three-months ended March 31, 2024. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2024. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.   Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ, for the year ended December 31, 2023.
Principles of Consolidation	Principles of Consolidation   The consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.
Use of Estimates	Use of Estimates   The preparation of condensed interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted   In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023 and interim periods within annual periods beginning after December 15, 2024, and early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024, early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements.

STOCK OPTIONS (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	1. The following table presents the Company’s stock option activity during the three months ended March 31, 2024:       Number of Options     Weighted Average Exercise Price   Outstanding at December 31,2023     36,602,000,000       0.001   Granted     -       -   Exercised     -       -   Forfeited or expired     -       -   Outstanding at March 31,2024     36,602,000,000       0.001   Number of options exercisable at March 31, 2024     14,000,000,000       0.001
SCHEDULE OF STOCK OPTIONS OUTSTANDING RANGE OF EXERCISE PRICE	The stock options outstanding as of March 31, 2024, have been separated into exercise prices, as follows:   Exercise price     Stock options outstanding     Weighted average remaining contractual life – years     Stock options vested         As of March 31, 2024   0.001       36,602,000,000       2.50       14,000,000,000           36,602,000,000       2.50       14,000,000,000     The stock options outstanding as of March 31, 2023, have been separated into exercise prices, as follows:   Exercise price     Stock options outstanding     Weighted average remaining contractual life – years     Stock options vested         As of March 31, 2023   0.001       46,602,000,000       3.50       9,600,000,000           46,602,000,000       3.50       9,600,000,000

RELATED PARTIES (Tables)	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
SCHEDULE OF RELATED PARTY EXPENSES	A. Transactions and balances with related parties       2024     2023       Three months ended March 31       2024     2023       (Unaudited)     (Unaudited)                 General and administrative expenses:                 Salaries and fees to officers     396,199       806,943   (*) of which share based compensation     352,171       756,077                     Research and development expenses:                 Salaries and fees to officers     49,191       77,811   (*) of which share based compensation     27,029       51,979       B. Balances with related parties and officers:       2024     2023       As of March 31,     As of December 31,       2024     2023       (Unaudited)                           Other current assets     71,149       62,647   Other accounts liabilities     116,001       113,615   Liability for employee rights upon retirement     127,359       129,768   Long term loan from related party (*)     2,012,339       2,012,339       (*) Received from UCG by December 31, 2021. The loan bears no interest.

GENERAL (Details Narrative) - USD ($)							3 Months Ended
	May 17, 2023	Oct. 25, 2022	Jul. 13, 2022	Mar. 22, 2022	Dec. 03, 2021	Apr. 27, 2020	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Nov. 01, 2022	Oct. 07, 2021	Dec. 31, 2020
Common stock, shares authorized							750,000,000,000		750,000,000,000
Common stock par value							$ 0.00001		$ 0.00001
Stock issued during period, value, new issues								$ 529,000
Shares issued, exercised
Stockholders' Equity, Reverse Stock Split	Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (“Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 20,000-to-1 and 60,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s Board of Directors. Pursuant to the Reverse Stock Split, each one thousand or fifteen thousand shares of common stock, or any other figure within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the Secretary of the State of Delaware.
Profit loss							$ 1,407,411	2,477,312
Net cash operating activities							469,874	$ 282,468
Cash and cash equivalent							113,000
Accumulated deficit							24,398,373		$ 23,015,196
Investments							3,000,000
Subscriptions receivable amount							1,694,767
Common Stock [Member]
Number of shares issued								1,640,000,000
Common stock, shares authorized											750,000,000,000	110,000,000,000
Common stock par value											$ 0.00001	$ 0.0007
Stock issued during period, value, new issues								$ 16,400
Profit loss
UCG, INC. [Member] | Common Stock [Member]
Stock issued during period, shares, conversion					387,000,000,000
Series B Preferred Stock [Member] | UCG, INC. [Member]
Stock issued during period, shares, conversion					3,870,000
Merger Agreement [Member] | Series B Preferred Stock [Member]
Number of shares converted						100,000
Number of common stock issued on conversion						387,000,000,000
Merger Agreement [Member] | Series B Preferred Stock [Member] | UCG, INC. [Member]
Number of shares issued						3,870,000
Preferred stock, par value						$ 0.0007
Cross Mobile Investment Agreement [Member] | Giora Rosenzweig [Member] | Cross Mobbnile [Member]
Equity method investment, ownership percentage				40.67%
Cross Mobile Investment Agreement [Member] | George Baumoehl [Member] | Cross Mobbnile [Member]
Equity method investment, ownership percentage				3.33%
Cross Mobile Investment Agreement [Member] | Common Stock [Member]
Common stock outstanding, rate				26.00%
Restricted number of shares issued			10,000,000,000	10,000,000,000
Stock issued during period, value, new issues			$ 4,000,000
Cross Mobile Investment Agreement [Member] | Common Stock [Member] | Cross Mobile [Member]
Percentage of hold outstanding share capital on fullly diluted basis		51.00%
Asset acquisition, percentage		25.00%
Shares issued, exercised		10,000,000
Cross Mobile Investment Agreement [Member] | Common Stock [Member] | Cross Mobile [Member] | Minimum [Member]
Common stock outstanding, rate		26.00%
Cross Mobile Investment Agreement [Member] | Common Stock [Member] | Cross Mobile [Member] | Maximum [Member]
Common stock outstanding, rate		51.00%
Investment Agreement [Member] | Maximum [Member]
Investments										$ 3,000,000

COMMON STOCK (Details Narrative) - USD ($)			3 Months Ended
	Feb. 29, 2024	Jan. 31, 2024	Mar. 31, 2024	Mar. 31, 2023
Procceds from subscripition Receivable				$ 60,000
Share price			$ 0.0002
Mr Baumeohll [Member]
Procceds from subscripition Receivable	$ 470,173	$ 470,173
Common stock shares, issued	1,174,417,500	1,174,417,500
Share price	$ 0.0004	$ 0.0004

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Options, Outstanding Balance | shares	36,602,000,000
Weighted Average Exercise Price, Outstanding Balance | $ / shares	$ 0.001
Number of Options, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Number of Options, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Options, Forfeited or expired | shares
Weighted Average Exercise Price, Forfeited or expired | $ / shares
Number of Options, Outstanding Balance | shares	36,602,000,000
Weighted Average Exercise Price, Outstanding Balance | $ / shares	$ 0.001
Number of Options, Outstanding Ending exercisable | shares	14,000,000,000
Weighted Average Exercise Price, Ending exercisable | $ / shares	$ 0.001

SCHEDULE OF STOCK OPTIONS OUTSTANDING RANGE OF EXERCISE PRICE (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Offsetting Assets [Line Items]
Stock options outstanding	36,602,000,000	46,602,000,000
Weighted average remaining contractual life- years	2 years 6 months	3 years 6 months
Stock options vested	14,000,000,000	9,600,000,000
Exercise Price Range One [Member]
Offsetting Assets [Line Items]
Exercise price	$ 0.001	$ 0.001
Stock options outstanding	36,602,000,000	46,602,000,000
Weighted average remaining contractual life- years	2 years 6 months	3 years 6 months
Stock options vested	14,000,000,000	9,600,000,000

STOCK OPTIONS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Aggregate intrinsic value outstanding	$ 3,660,200
Share price per share	$ 0.0002
Stock-based compensation	$ 972,750	$ 2,219,109
Unrecognized share based compensation	$ 3,315,588
Unrecognized share based compensation, period	1 year 4 months 20 days

SCHEDULE OF RELATED PARTY EXPENSES (Details) - USD ($)		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Other Assets, Current		$ 191,322		$ 148,749
Related Party [Member]
Related Party Transaction [Line Items]
Other Assets, Current		71,149		62,647
Accounts Payable, Other, Current		116,001		113,615
[custom:LiabilityForEmployeeRightsUponRetirement-0]		127,359		129,768
Other Liabilities	[1]	2,012,339		$ 2,012,339
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Balance with related parties		396,199	$ 806,943
General and Administrative Expense [Member] | Share-based Compensation [Member]
Related Party Transaction [Line Items]
Balance with related parties	[1]	352,171	756,077
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Balance with related parties		49,191	77,811
Research and Development Expense [Member] | Share-based Compensation [Member]
Related Party Transaction [Line Items]
Balance with related parties	[1]	$ 27,029	$ 51,979
[1] Received from UCG by December 31, 2021. The loan bears no interest.

---